Allergic rhinitis (AR), specifically moderate-severe persistent allergic rhinitis (PER)
Conditions
Interventions
Zangfu Syndrome Differentiation Acupuncture Group:Acupoints: Bilateral Yingxiang, Yintang, Dazhui, Fengmen, Feishu. Operation: Seated position. Yingxiang: 0.3-0.5 cun subcutaneous towards nasal root
Yintang: 0.8-1 cun subcutaneous towards nasal root
Dazhui: 1 cun perpendicular
Fengmen/Feishu: 0.5-0.8 cun oblique towards spine. Neutral manipulation after deqi, 20-minute retention. 3 sessions/week for 4 weeks.
Meridian Syndrome Differentiation Acupuncture Group:Acupoints: Bilateral Yingxiang, Yintang, Hegu, Quchi, Zusanli. Operation: Supine position. Yingxiang/Yintang as above
Hegu: 0.5-1.0 cun perpendicular
Quchi/Zusanli: 1.0-1.5 cun perpendicular. Neutral manipulation after deqi, 20-minute retention. 3 sessions/week for 4 weeks.
Sponsors
Dongzhimen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Meet the diagnostic criteria for moderate to severe persistent allergic rhinitis; (2) Have a history of moderate to severe persistent allergic rhinitis for at least 2 years or more; (3) Total nasal symptom score (TNSS) =4 within one week before enrollment; (4) Age between 18 and 65 (inclusive), with no gender restrictions; (5) Be capable of accurately expressing personal wishes, voluntarily complete the informed consent form, and agree to participate in the clinical trial. All five criteria must be met simultaneously for inclusion.
Exclusion criteria
Exclusion criteria: (1) Individuals with a history of chronic sinusitis or diagnosed with chronic sinusitis via sinus X-ray examination; (2) Those with organic lesions in the nasal cavity or who have undergone nasal surgery; (3) Patients who have suffered from respiratory infections or acute sinusitis within the past 2 weeks, or those showing signs of inflammation on chest X-rays; (4) Patients who have received Western medicine (H1-antihistamines, glucocorticoids, leukotriene receptor antagonists, mast cell membrane stabilizers, decongestants, anticholinergics, etc.) or traditional Chinese medicine treatments via the nasal, oral, or systemic routes within the past 2 weeks; (5) Individuals who have undergone physical therapies within the scope of traditional Chinese medicine or other traditional medical practices, such as needle, moxibustion, cupping, or nasal inhalation of Chinese herbal medicine, within the past 2 weeks; (6) Patients who have received specific immunotherapy or systemic hormone treatment within the past year; (7) Those with concurrent respiratory diseases, such as asthma; (8) Patients with severe respiratory, cardiovascular, hepatic, splenic, renal, hematopoietic system diseases, mental disorders, or infectious diseases; (9) Pregnant, lactating, or women planning pregnancy during the study period; (10) Individuals with any contraindications for acupuncture, scarring or infection at the treatment site, or systemic conditions deemed unsuitable for intervention by the researcher; (11) Diseases affecting body temperature, such as the common cold, influenza, hyperthyroidism, hypothyroidism, acute thyroiditis, subacute thyroiditis, etc.; (12) Lesions, skin injuries, sensory impairments, scars, or tumors at the testing site; (13) Participants deemed uncooperative for clinical research by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Nasal Symptom Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Total Nasal-associated Symptom Score;Rhinoconjunctivitis Quality of Life Questionnaire;Rhinitis Control Assessment Test;Rescue Medication Score;Patient Satisfaction/Acceptance;Infrared thermography detection; | — |
Countries
China
Contacts
Public ContactZhao Jiping
Beijing University of Chinese Medicine Dongzhimen Hospital
Outcome results
None listed